Calamos Advisors
ABBV icon

Calamos Advisors’s AbbVie ABBV Stock Holding History

Calamos Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20,400
Closed -$4.27M – 920
2025
Q2 		$4.27M Buy
+20,400
New +$3.79M 0.02% 567

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Calamos Advisors's ABBV Position: Q1 2026 in Review

Calamos Advisors increased its AbbVie (ABBV) stake by 3.7% in Q1 2026, buying an estimated $3.86M and bringing the position to 483,670 shares worth $105M. The position accounts for 0.37% of the portfolio, ranked #50.

Calamos Advisors first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $107M in Q1 2018. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Calamos Advisors held 483,670 shares of AbbVie worth $105M as of Q1 2026.
  • Calamos Advisors bought 17,380 AbbVie shares in Q1 2026, an estimated $3.86M.
  • AbbVie made up 0.37% of Calamos Advisors's portfolio in Q1 2026, its #50 holding.
  • Calamos Advisors first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Calamos Advisors's AbbVie position peaked at $107M in Q1 2018.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Calamos Advisors's 13F filing for Q1 2026, filed 4 May 2026.